{
  "docId": "019de077-0cc2-77db-9351-9943b4f00de7",
  "docSlug": "7bc984921da16d0e07defb66ba0ce0a1",
  "documentTitle": "Immix Biopharma | Investor Presentation Deck | 56 slides",
  "authorId": "immix-biopharma",
  "authorName": "Immix Biopharma",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2024-03-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 20,
  "pageCount": 56,
  "prevPage": 19,
  "nextPage": 21,
  "slideType": "solution",
  "function": "present_solution",
  "density": "overcrowded",
  "nDataPoints": 0,
  "notes": "Includes citations from Nature Medicine and Signal Transduction and Targeted Therapy to validate the scientific approach.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de077-0cc2-77db-9351-9943b4f00de7/20",
  "deckHref": "/decks/019de077-0cc2-77db-9351-9943b4f00de7",
  "deckJsonHref": "/decks/019de077-0cc2-77db-9351-9943b4f00de7.json",
  "deckAnchorHref": "/decks/019de077-0cc2-77db-9351-9943b4f00de7#slide-20",
  "components": [
    {
      "bbox": {
        "h": 0.25,
        "w": 0.3,
        "x": 0.67,
        "y": 0.21
      },
      "kind": "callout",
      "text": "Nature Signal Transduction and Targeted Therapy citation and quote",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "1fb534be-b08d-45ce-b547-ebe95c516515",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.35,
        "w": 0.45,
        "x": 0.52,
        "y": 0.52
      },
      "kind": "callout",
      "text": "Nature Medicine and MSKCC citation and quote",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a78ca752-0e47-4510-aa11-0499bcc6a765",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.3,
        "w": 0.1,
        "x": 0.52,
        "y": 0.22
      },
      "kind": "image",
      "text": "Diagram of CD3/4-1BB receptor structure",
      "attrs": null,
      "subkind": "illustration",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c55a27df-214b-40d3-a319-ee3e4af409e8",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.45,
        "x": 0.04,
        "y": 0.38
      },
      "kind": "paragraph",
      "text": "NXC-201 adds a positively charged amino acid (lysine) next to a tyrosine phosphorylation site, therefore: Long CRS duration causes extended cardiovascular stress; There is a limited ability to manage toxicities in this population with conventional methods",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "3b8008a9-29b8-4373-98d6-f152e49db64a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.45,
        "x": 0.04,
        "y": 0.23
      },
      "kind": "paragraph",
      "text": "CARs rely on activation of CAR-T cells through CD3ζ derived immunoreceptor tyrosine-based activation motifs (ITAMs), typically 3 ITAM motifs per CAR",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "63b2ad6d-cfc5-484a-923a-dd25b20e647c",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.45,
        "x": 0.04,
        "y": 0.62
      },
      "kind": "paragraph",
      "text": "The combined effect of these modifications is to drive a “digital” signaling of extracellular activity, that is on when antigen is present and off when not",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a0f06721-0419-4d97-b5bb-afb786100182",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.45,
        "x": 0.04,
        "y": 0.78
      },
      "kind": "paragraph",
      "text": "Modification of ITAMs is a common theme in third-generation CAR design, with publications in Nature Medicine and by Memorial Sloan Kettering on the topic",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b4f4716d-d5f2-4014-97cc-d4c1bdd3cb9a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.75,
        "x": 0.06,
        "y": 0.05
      },
      "kind": "title",
      "text": "Proprietary Optimized CD3ζ + CD8 Delivers “Digital” Intracellular Signaling, Eliminates Neurotoxicity, Reduces CRS Duration",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "0ef5eeb5-9195-4b67-ad2a-ae4a745671a7",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Logical chain",
      "slug": "logical-chain",
      "agent": null,
      "layer": "slide",
      "matchId": "28c6e7cb-c6de-462b-9fd9-a9c24ad24d07",
      "evidence": "CARs rely on activation of CAR-T cells through CD3ζ derived immunoreceptor tyrosine-based activation motifs (ITAMs), typically 3 ITAM motifs per CAR",
      "confidence": 0.7
    }
  ],
  "frameworks": [
    {
      "name": "authority-citation",
      "slug": null,
      "matchId": "9a795eeb-872d-4720-a672-2d355b0174e2",
      "evidence": "Citing Nature Medicine and Nature Signal Transduction and Targeted Therapy to support the scientific mechanism.",
      "confidence": 0.9
    }
  ],
  "arcBeats": [],
  "loops": [
    {
      "to": 23,
      "from": 16,
      "name": "Quick Win Big Bet",
      "slug": "47-quick-win-big-bet",
      "bestFor": "Transformation planning, 100-day plans, resource allocation",
      "matchId": "9e3ff9b5-ae74-4c1c-8a8b-4b20ea131916",
      "evidence": "Slides 16-23 present clinical trial results and market opportunity for NXC-201",
      "position": 1,
      "objective": "What are the potential benefits of NXC-201 in the market?",
      "structure": "The Full List -> Quick Wins (Low effort, High impact) -> Big Bets (High effort, High impact) -> Sequenced Roadmap",
      "confidence": 0.6,
      "description": "Separate initiatives into immediate wins and longer-term strategic bets"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}